Altered host-microbe interaction in HIV: A target for intervention with pro- and prebiotics

International Reviews of Immunology

Volumn 29, Issue 5, 2010, Pages 485-513

  Hummelen, Ruben ^a,b   Vos, Arjan P ^c,d   Van'T Land, Belinda ^c,d   Van Norren, Klaske ^d,e   Reid, Gregor ^b,f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c UTRECHT UNIVERSITY   (Netherlands)

^d DANONE RESEARCH   (Netherlands)

^e WAGENINGEN UNIVERSITY   (Netherlands)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

AIDS; bacterial translocation; gastrointestinal tract; HIV; prebiotics; probiotics

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL INFECTION; HOMEOSTASIS; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOMODULATION; INTESTINE FLORA; INTESTINE FUNCTION; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH1 CELL; VIRUS REPLICATION;

HIV; HIV ENTEROPATHY; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATION; INTESTINES; METAGENOME; PROBIOTICS; TH1-TH2 BALANCE; VIRUS REPLICATION;

EID: 77956671143     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2010.505310     Document Type: Review

References (181)

1. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 2008;8:411-420.
2. Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 2009;106:3698-3703.
3. Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science 2005;307:1915-1920.
4. Duerkop BA, Vaishnava S, Hooper LV. Immune responses to the microbiota at the intestinal mucosal surface. Immunity 2009;31:368-376.
5. Johansson ME, Phillipson M, Petersson J, et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci USA 2008;105:15064-15069.
6. Wells JM, Loonen LM, Karczewski JM. The role of innate signaling in the homeostasis of tolerance and immunity in the intestine. Int J Med Microbiol 2009;300:41-48.
7. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-241.
8. Strober W, Murray PJ, Kitani A, et al. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006;6:9-20.
9. Kraehenbuhl JP, Neutra MR. Epithelial M cells: Differentiation and function. Annu Rev Cell Dev Biol 2000;16:301-332.
10. Sato A, Iwasaki A. Peyer's patch dendritic cells as regulators of mucosal adaptive immunity. Cell Mol Life Sci 2005;62:1333-1338.
11. Roberts SJ, Smith AL, West AB, et al. T-cell alpha beta + and gamma delta + deficient mice display abnormal but distinct phenotypes toward a natural, widespread infection of the intestinal epithelium. Proc Natl Acad Sci USA 1996;93:11774-11779.
12. Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001;2:361-367.
13. Coombes JL, Powrie F. Dendritic cells in intestinal immune regulation. Nat Rev Immunol 2008;8:435-446.
14. Barnes MJ, Powrie F. Regulatory T cells reinforce intestinal homeostasis. Immunity 2009;31:401-411.
15. Baba N, Samson S, Bourdet-Sicard R, et al. Commensal bacteria trigger a full dendritic cell maturation program that promotes the expansion of non-Tr1 suppressor T cells. J Leukoc Biol 2008;84:468-476.
16. Rook GA, Brunet LR. Microbes, immunoregulation, and the gut. Gut 2005;54:317-320.
17. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004;303:1662-1665.
18. Suzuki K, Meek B, Doi Y, et al. Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci USA 2004;101:1981-1986.
19. Smith K, McCoy KD, Macpherson AJ. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Semin Immunol 2007;19:59-69.
20. Ayabe T, Satchell DP, Wilson CL, et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000;1:113-118.
21. Vaishnava S, Behrendt CL, Ismail AS, et al. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci USA 2008;105:20858-20863.
22. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004;5:104-112.
23. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000;289:1560-1563.
24. Kelly D, Conway S, Aminov R. Commensal gut bacteria: mechanisms of immune modulation. Trends Immunol 2005;26:326-333.
25. Niess JH, Leithauser F, Adler G, et al. Commensal gut flora drives the expansion of proinflammatory CD4 T cells in the colonic lamina propria under normal and inflammatory conditions. J Immunol 2008;180:559-568.
26. Imaoka A, Matsumoto S, Setoyama H, et al. Proliferative recruitment of intestinal intraepithelial lymphocytes after microbial colonization of germ-free mice. Eur J Immunol 1996;26:945-948.
27. Ahern PP, Izcue A, Maloy KJ, et al. The interleukin-23 axis in intestinal inflammation. Immunol Rev 2008;226:147-159.
28. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421:744-748.
29. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008;28:454-467.
30. van de Veerdonk FL, Gresnigt MS, Kullberg BJ, et al. Th17 responses and host defense against microorganisms: An overview. BMB Rep 2009;42:776-787.
31. Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: A (co-)evolutionary perspective. Nat Rev Immunol 2009;9:883-889.
32. Atarashi K, Nishimura J, Shima T, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008;455:808-812.
33. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008;453:620-625.
34. Katakura K, Lee J, Rachmilewitz D, et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 2005;115:695-702.
35. Kotler DP, Reka S, Borcich A, et al. Detection, localization, and quantitation of HIV-associated antigens in intestinal biopsies from patients with HIV. Am J Pathol 1991;139:823-830.
36. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004;200:761-770.
37. Lim SG, Condez A, Poulter LW. Mucosal macrophage subsets of the gut in HIV: Decrease in antigen-presenting cell phenotype. Clin Exp Immunol 1993;92:442-447.
38. Nilssen DE, Muller F, Oktedalen O, et al. Intraepithelial gamma/delta T cells in duodenal mucosa are related to the immune state and survival time in AIDS. J Virol 1996;70:3545-3550.
39. Poccia F, Piselli P, Vendetti S, et al. Heat-shock protein expression on the membrane of T cells undergoing apoptosis. Immunology 1996;88:6-12.
40. Sankaran S, Guadalupe M, Reay E, et al. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci USA 2005;102:9860-9865.
41. Lim SG, Menzies IS, Lee CA, et al. Intestinal permeability and function in patients infected with human immunodeficiency virus. A comparison with coeliac disease. Scand J Gastroenterol 1993;28:573-580.
42. Kelly P, Todd J, Sianongo S, et al. Susceptibility to intestinal infection and diarrhoea in Zambian adults in relation to HIV status and CD4 count. BMC Gastroen-terol 2009;9:7.
43. Knox TA, Spiegelman D, Skinner SC, et al. Diarrhea and abnormalities of gastrointestinal function in a cohort of men and women with HIV infection. Am J Gastroenterol 2000;95:3482-3489.
44. McCune JM. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 2001;410:974-979.
45. Duh EJ, Maury WJ, Folks TM, et al. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 1989;86:5974-5978.
46. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999;179:859-870.
47. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003;77:11708-11717.
48. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.
49. Emu B, Sinclair E, Favre D, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005;79:14169-14178.
50. Ferre AL, Hunt PW, Critchfield JW, et al. Mucosal immune responses to HIV-1 in elite controllers: A potential correlate of immune control. Blood 2009;113:3978-3989.
51. Maresca M, Mahfoud R, Garmy N, et al. The virotoxin model of HIV-1 enteropa-thy: Involvement of GPR15/Bob and galactosylceramide in the cytopathic effects induced by HIV-1 gp120 in the HT-29-D4 intestinal cell line. J Biomed Sci 2003;10:156-166.
52. George MD, Reay E, Sankaran S, et al. Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol 2005;79:2709-2719.
53. Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 2008;22:2035-2038.
54. MacFie J, O'Boyle C, Mitchell CJ, et al. Gut origin of sepsis: A prospective study investigating associations between bacterial translocation, gastric microflora, and septic morbidity. Gut 1999;45:223-228.
55. Ersoz G, Aydin A, Erdem S, et al. Intestinal permeability in liver cirrhosis. Eur J Gastroenterol Hepatol 1999;11:409-412.
56. Cooke KR, Olkiewicz K, Erickson N, et al. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J Endotoxin Res 2002;8:441-448.
57. Caradonna L, Amati L, Magrone T, et al. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: Biological and clinical significance. J Endotoxin Res 2000;6:205-214.
58. Wyatt J, Vogelsang H, Hubl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993;341:1437-1439.
59. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007;104:13780-13785.
60. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-484.
61. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut mi-crobiome with increased capacity for energy harvest. Nature 2006;444:1027-1031.
62. Gori A, Tincati C, Rizzardini G, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol 2008;46:757-758.
63. Wolf BW, Wheeler KB, Ataya DG, et al. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food Chem Toxicol 1998;36:1085-1094.
64. McKenna P, Hoffmann C, Minkah N, et al. The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis. PLoS Pathog 2008;4:e20.
65. Sindhu S, Toma E, Cordeiro P, et al. Relationship of in vivo and ex vivo levels of TH1 and TH2 cytokines with viremia in HAART patients with and without opportunistic infections. J Med Virol 2006;78:431-439.
66. Buonaguro L, Tornesello MS, Gallo RC, et al. Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles. J Virol 2009;83:304-313.
67. Israel-Biet D, Labrousse F, Tourani JM, et al. Elevation of IgE in HIV-infected subjects: A marker of poor prognosis. J Allergy Clin Immunol 1992;89:68-75.
68. Wright DN, Nelson Jr. RP, Ledford DK, et al. Serum IgE and human immunodeficiency virus (HIV) infection. J Allergy Clin Immunol 1990;85:445-452.
69. Becker Y. The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers\-Review and hypothesis. Virus Genes 2003;28:5-18.
70. Rancinan C, Morlat P, Chene G, et al. Prevalence of clinical manifestations of allergic reactions in HIV infection. Cross sectional study of 115 subjects. Rev Med Interne 1997;18:691-694.
71. Harrer T, Harrer E, Kalams SA, et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996;12:585-592.
72. Ullum H, Cozzi Lepri A, Bendtzen K, et al. Low production of interferon gamma is related to disease progression in HIV infection: Evidence from a cohort of 347 HIV-infected individuals. AIDS Res Hum Retroviruses 1997;13:1039-1046.
73. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-1132.
74. Food and Agriculture Organization of the United Nations (FAO). Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria, 2001. Available at: www.who.int/foodsafety/publications/ fs management/en/probiotics.pdf (accessed June 11, 2010).
75. Ukena SN, Singh A, Dringenberg U, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007;2:e1308.
76. Zyrek AA, Cichon C, Helms S, et al. Molecular mechanisms underlying the pro-biotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007;9:804-816.
77. Resta-Lenert S, Barrett KE. Probiotics and commensals reverse TNF-alpha-and IFN-gamma-induced dysfunction in human intestinal epithelial cells. Gastroen-terology 2006;130:731-746.
78. Yan F, Cao H, Cover TL, et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007;132:562-575.
79. Luyer MD, Buurman WA, Hadfoune M, et al. Strain-specific effects of pro-biotics on gut barrier integrity following hemorrhagic shock. Infect Immun 2005;73:3686-3692.
80. Wang Z, Xiao G, Yao Y, et al. The role of bifidobacteria in gut barrier function after thermal injury in rats. J Trauma 2006;61:650-657.
81. Isolauri E, Majamaa H, Arvola T, et al. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroen-terology 1993;105:1643-1650.
82. Forsyth CB, Farhadi A, Jakate SM, et al. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 2009;43:163-172.
83. Kotzampassi K, Giamarellos-Bourboulis EJ, Voudouris A, et al. Benefits of a synbiotic formula (Synbiotic 2000 Forte) in critically ill trauma patients: Early results of a randomized controlled trial. World J Surg 2006;30:1848-1855.
84. Alberda C, Gramlich L, Meddings J, et al. Effects of probiotic therapy in critically ill patients: A randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2007;85:816-823.
85. Shimizu K, Ogura H, Goto M, et al. Synbiotics decrease the incidence of septic complications in patients with severe SIRS: A preliminary report. Dig Dis Sci 2009;54:1071-1078.
86. Rayes N, Seehofer D, Theruvath T, et al. Supply of pre-and probiotics reduces bacterial infection rates after liver transplantation\-A randomized, double-blind trial. Am J Transplant 2005;5:125-130.
87. Sugawara G, Nagino M, Nishio H, et al. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: A randomized controlled trial. Ann Surg 2006;244:706-714.
88. Reddy BS, Macfie J, Gatt M, et al. Randomized clinical trial of effect of synbiotics, neomycin and mechanical bowel preparation on intestinal barrier function in patients undergoing colectomy. Br J Surg 2007;94:546-554.
89. Jain PK, McNaught CE, Anderson AD, et al. Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: A randomised controlled trial. Clin Nutr 2004;23:467-475.
90. Anderson AD, McNaught CE, Jain PK, et al. Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut 2004;53:241-245.
91. McNaught CE, Woodcock NP, MacFie J, et al. A prospective randomised study of the probiotic Lactobacillus plantarum 299V on indices of gut barrier function in elective surgical patients. Gut 2002;51:827-831.
92. Grabig A, Paclik D, Guzy C, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways. Infect Immun 2006;74:4075-4082.
93. Ewaschuk JB, Backer JL, Churchill TA, et al. Surface expression of Toll-like receptor 9 is upregulated on intestinal epithelial cells in response to pathogenic bacterial DNA. Infect Immun 2007;75:2572-2579.
94. Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004;126:1358-1373.
95. Foligne B, Zoumpopoulou G, Dewulf J, et al. A key role of dendritic cells in probiotic functionality. PLoS ONE 2007;2:e313.
96. Di Giacinto C, Marinaro M, Sanchez M, et al. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 2005;174:3237-3246.
97. Kwon HK, Lee CG, So JS, et al. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci USA 2010;107:2159-2164.
98. O'Mahony L, O'Callaghan L, McCarthy J, et al. Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am J Physiol Gastrointest Liver Physiol 2006;290:G839-G845. 99.
99. Von der Weid T, Bulliard C, Schiffrin EJ. Induction by a lactic acid bacterium of a population of CD4(+) T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10. Clin Diagn Lab Immunol 2001;8:695-701.
100. Baroja ML, Kirjavainen PV, Hekmat S, et al. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol 2007;149:470-479.
101. Miettinen M, Vuopio-Varkila J, Varkila K. Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun 1996;64:5403-5405.
102. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105:16731-16736.
103. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-551.
104. Braat H, Van Den Brande J, van Tol E, et al. Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am J Clin Nutr 2004;80:1618-1625.
105. Pessi T, Sutas Y, Hurme M, et al. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy 2000;30:1804-1808.
106. Iwabuchi N, Takahashi N, Xiao JZ, et al. Suppressive effects of Bifidobac-terium longum on the production of Th2-attracting chemokines induced with T cell-antigen-presenting cell interactions. FEMS Immunol Med Microbiol 2009;55:324-334.
107. Hougee S, Vriesema AJ, Wijering SC, et al. Oral treatment with probiotics reduces allergic symptoms in ovalbumin-sensitized mice: A bacterial strain comparative study. Int Arch Allergy Immunol 2009;151:107-117.
108. Mohamadzadeh M, Olson S, Kalina WV, et al. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci USA 2005;102:2880-2885.
109. Viljanen M, Savilahti E, Haahtela T, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: A double-blind placebo-controlled trial. Allergy 2005;60:494-500.
110. Viljanen M, Pohjavuori E, Haahtela T, et al. Induction of inflammation as a possible mechanism of probiotic effect in atopic eczema-dermatitis syndrome. J Allergy Clin Immunol 2005;115:1254-1259.
111. Pohjavuori E, Viljanen M, Korpela R, et al. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. J Allergy Clin Immunol 2004;114:131-136.
112. Pritts T, Hungness E, Wang Q, et al. Mucosal and enterocyte IL-6 production during sepsis and endotoxemia\-Role of transcription factors and regulation by the stress response. Am J Surg 2002;183:372-383.
113. Fujihashi K, McGhee JR, Lue C, et al. Human appendix B cells naturally express receptors for and respond to interleukin 6 with selective IgA1 and IgA2 synthesis. J Clin Invest 1991;88:248-252.
114. Isolauri E, Arvola T, Sutas Y, et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000;30:1604-1610.
115. Rosenfeldt V, Benfeldt E, Nielsen SD, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003;111:389-395.
116. Brouwer ML, Wolt-Plompen SA, Dubois AE, et al. No effects of probiotics on atopic dermatitis in infancy: A randomized placebo-controlled trial. Clin Exp Allergy 2006;36:899-906.
117. Kaila M, Isolauri E, Soppi E, et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992;32:141-144.
118. Schlee M, Wehkamp J, Altenhoefer A, et al. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 2007;75:2399-2407.
119. Spinler JK, Taweechotipatr M, Rognerud CL, et al. Human-derived probiotic Lac-tobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe 2008;14:166-171.
120. Heinemann C, van Hylckama Vlieg JE, Janssen DB, et al. Purification and characterization of a surface-binding protein from Lactobacillus fermentum RC-14 that inhibits adhesion of Enterococcus faecalis 1131. FEMS Microbiol Lett 2000;190:177-180.
121. Frick JS, Fink K, Kahl F, et al. Identification of commensal bacterial strains that modulate Yersinia enterocolitica and dextran sodium sulfate-induced inflammatory responses: Implications for the development of probiotics. Infect Immun 2007;75:3490-3497.
122. Laughton JM, Devillard E, Heinrichs DE, et al. Inhibition of expression of a staphylococcal superantigen-like protein by a soluble factor from Lactobacillus reuteri. Microbiology 2006;152:1155-1167.
123. Alak JI, Wolf BW, Mdurvwa EG, et al. Effect of Lactobacillus reuteri on intestinal resistance to Cryptosporidium parvum infection in a murine model of acquired immunodeficiency syndrome. J Infect Dis 1997;175:218-221.
124. Mohan R, Koebnick C, Schildt J, et al. Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm infants: A double-blind, placebo-controlled, randomized study. J Clin Microbiol 2006;44:4025-4031.
125. Plummer SF, Garaiova I, Sarvotham T, et al. Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy. Int J Antimicrob Agents 2005;26:69-74.
126. Sonnenburg JL, Chen CT, Gordon JI. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol 2006;4:e413.
127. Allen SJ, Okoko B, Martinez E, et al. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev, CD003048, 2004.
128. Heiser CR, Ernst JA, Barrett JT, et al. Probiotics, soluble fiber, and L-glutamine (GLN) reduce nelfinavir (NFV)-or lopinavir/ritonavir (LPV/r)-related diarrhea. J Int Assoc Physicians AIDS Care (Chic Ill) 2004;3:121-129.
129. Salminen MK, Tynkkynen S, Rautelin H, et al. The efficacy and safety of probiotic Lactobacillus rhamnosus GGonprolonged, noninfectious diarrheainHIV patients on antiretroviral therapy: A randomized, placebo-controlled, crossover study. HIV Clin Trials 2004;5:183-191.
130. Trois L, Cardoso EM, Miura E. Use of probiotics in HIV-infected children: A randomized double-blind controlled study. J Trop Pediatr 2008;54:19-24.
131. Anukam KC, Osazuwa EO, Osadolor HB, et al. Yogurt containing probiotic Lac-tobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/AIDS patients. J Clin Gastroenterol 2008;42:239-243.
132. Kerac M, Bunn J, Seal A, et al. Probiotics and prebiotics for severe acute malnutrition (PRONUT study): A double-blind efficacy randomised controlled trial in Malawi. Lancet 2009;374:136-144.
133. Horwitch CA, Furseth HA, Larson AM, et al. Lactobacillemia in three patients with AIDS. Clin Infect Dis 1995;21:1460-1462.
134. Rogasi PG, Vigano S, Pecile P, et al. Lactobacillus casei pneumonia and sepsis in a patient with AIDS. Case report and review of the literature. Ann Ital Med Int 1998;13:180-182.
135. Abgrall S, Joly V, Derkinderen P, et al. Lactobacillus casei infection in an AIDS patient. Eur J Clin Microbiol Infect Dis 1997;16:180-182.
136. Pineiro M, Asp NG, Reid G, et al. FAO Technical meeting on prebiotics. J Clin Gastroenterol 2008;42(Suppl 3 Pt 2):S156-S159.
137. Knol J, Scholtens P, Kafka C, et al. Colon microflora in infants fed formula with galacto-and fructo-oligosaccharides: More like breast-fed infants. J Pediatr Gas-troenterol Nutr 2005;40:36-42.
138. Scholtens PA, Alles MS, Bindels JG, et al. Bifidogenic effects of solid weaning foods with added prebiotic oligosaccharides: A randomised controlled clinical trial. J Pediatr Gastroenterol Nutr 2006;42:553-559.
139. Ramirez-Farias C, Slezak K, Fuller Z, et al. Effect of inulin on the human gut mi-crobiota: Stimulation of Bifidobacterium adolescentis and Faecalibacterium praus-nitzii. Br J Nutr 2009;101:541-550.
140. Vulevic J, Drakoularakou A, Yaqoob P, et al. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am J Clin Nutr 2008;88:1438-1446.
141. Rossi M, Corradini C, Amaretti A, et al. Fermentation of fructooligosaccharides and inulin by bifidobacteria: A comparative study of pure and fecal cultures. Appl Environ Microbiol 2005;71:6150-6158.
142. Kikuchi H, Andrieux C, Riottot M, et al. Effect of two levels of transgalactosy-lated oligosaccharide intake in rats associated with human faecal microflora on bacterial glycolytic activity, end-products of fermentation and bacterial steroid transformation. J Appl Bacteriol 1996;80:439-446.
143. Hernot DC, Boileau TW, Bauer LL, et al. In vitro fermentation profiles, gas production rates, and microbiota modulation as affected by certain fructans, galactooligosaccharides, and polydextrose. J Agric Food Chem 2009;57:1354-1361.
144. Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39:1441-1449.
145. Mutlu E, Keshavarzian A, Engen P, et al. Intestinal dysbiosis: A possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res 2009;33:1836-1846.
146. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009;58:1091-1103.
147. Willemsen LE, Koetsier MA, van Deventer SJ, et al. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut 2003;52:1442-1447.
148. Peng L, Li ZR, Green RS, et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 2009;139:1619-1625.
149. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: A randomized, controlled study. Clin Gastroenterol Hepatol 2005;3:442-448.
150. Cummings JH, Christie S, Cole TJ. A study of fructo oligosaccharides in the prevention of travellers' diarrhoea. Aliment Pharmacol Ther 2001;15:1139-1145.
151. Bruzzese E, Volpicelli M, Squeglia V, et al. A formula containing galacto-and fructo-oligosaccharides prevents intestinal and extra-intestinal infections: An observational study. Clin Nutr 2009;28:156-161.
152. Knol J, Boehm G, Lidestri M, et al. Increase of faecal bifidobacteria due to dietary oligosaccharides induces a reduction of clinically relevant pathogen germs in the faeces of formula-fed preterm infants. Acta Paediatr 2005;94(Suppl):31-33.
153. Scholtens PA, Alliet P, Raes M, et al. Fecal secretory immunoglobu-lin A is increased in healthy infants who receive a formula with short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides. J Nutr 2008;138:1141-1147.
154. Gibson GR, McCartney AL, Rastall RA. Prebiotics and resistance to gastrointestinal infections. Br J Nutr 2005;93(Suppl 1):S31-S34.
155. Schauber J, Dorschner RA, Yamasaki K, et al. Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvi-ronmental stimuli. Immunology 2006;118:509-519.
156. Newburg DS, Ruiz-Palacios GM, Morrow AL. Human milk glycans protect infants against enteric pathogens. Annu Rev Nutr 2005;25:37-58.
157. Tzortzis G, Goulas AK, Gee JM, et al. A novel galactooligosaccharide mixture increases the bifidobacterial population numbers in a continuous in vitro fermentation system and in the proximal colonic contents of pigs in vivo. J Nutr 2005;135:1726-1731.
158. Guggenbichler JP, De Bettignies-Dutz A, Meissner P, et al. Acidic oligosaccharides from natural sources block adherence of Escherichia coli on uroepithelial cells. Pharm Pharmacol Lett 1997;7:35-38.
159. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut 2005;54:242-249.
160. Welters CF, Heineman E, Thunnissen FB, et al. Effect of dietary insulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum 2002;45:621-627.
161. Lindsay JO, Whelan K, Stagg AJ, et al. Clinical, microbiological, and immuno-logical effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 2006;55:348-355.
162. Guarner F. Prebiotics in inflammatory bowel diseases. Br J Nutr 2007;98(Suppl 1):S85-S89.
163. Trevisi P, De Filippi S, Minieri L, et al. Effect of fructo- oligosaccharides and different doses of Bifidobacterium animalis in a weaning diet on bacterial translocation and Toll-like receptor gene expression in pigs. Nutrition 2008;24:1023-1029.
164. Leung CH, Lam W, Ma DL, et al. Butyrate mediates nucleotide-binding and oligomerisation domain 2-dependent mucosal immune responses against pepti-doglycan. Eur J Immunol 2009;39:3529-3537.
165. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem 2001;276:44641- 44646.
166. Schwab M, Reynders V, Loitsch S, et al. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signaling. Mol Immunol 2007;44:3625-3632.
167. van NorrenK, Dijk FJ, van't Land B, et al.et al. NF-κB-mediated HIV-1 production is inhibited in vitro by pectin derived acidic oligosaccharides (pAOS). Abstract no. WEPEA095. 5th IAS Conference on HIV Pathogenesis and Treatment, Cape Town, July 19-22, 2009.
168. Brown AJ, Goldsworthy SM, Barnes AA, et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003;278:11312-11319.
169. Le Poul E, Loison C, Struyf S, et al. Functional characterization of
170. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009;461:1282-1286.
171. Arslanoglu S, Moro GE, Schmitt J, et al. Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. J Nutr 2008;138:1091-1095.
172. van Hoffen E, Ruiter B, Faber J, et al. A specific mixture of short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides induces a beneficial im-munoglobulin profile in infants at high risk for allergy. Allergy 2009;64:484-487.
173. Clerici M, Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
174. Schouten B, van Esch BC, Hofman GA, et al. Cow milk allergy symptoms are reduced in mice fed dietary synbiotics during oral sensitization with whey. J Nutr 2009;139:1398-1403.
175. Vos AP, Haarman M, Buco A, et al. A specific prebiotic oligosaccharide mixture stimulates delayed-type hypersensitivity ina murine influenza vaccination model. Int Immunopharmacol 2006;6:1277-1286.
176. Vos AP, van Esch BC, Stahl B, et al. Dietary supplementation with specific oligosaccharide mixtures decreases parameters of allergic asthma in mice. Int Immunopharmacol 2007;7:1582-1587.
177. Molis C, Flourie B, Ouarne F, et al. Digestion, excretion, and energy value of fructooligosaccharides in healthy humans. Am J Clin Nutr 1996;64:324-328.
178. Ben Amor K, Rizzardini G, Torti C, et al.et al. Disturbed gut microbiota in HAART-naive HIV-1 positive adults: Effect of intervention with a specific prebiotic oligosac-charide mixture, Poster # 375b. 15th Conference on Retrovirus and Opportunistic Infections (CROI 2008), Boston, MA, February 3-6, 2008.
179. van't Land B, Benlhassan-Chahour K, Rizzardini G, et al.et al. A specific mixture of prebiotic oligosaccharides reduces hyper-immune activation and improves NK cell cytolytic activity in HAART-naive HIV positive adults, Poster # 723. 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008), Boston, MA, February 3-6, 2008.
180. Lange J, et al.et al. Reduced CD4+ T cell decline and immune activation by NR100157, a specific multi-targeted nutritional intervention, in HIV-1 positive adults not on antiretroviral therapy (BITE), Abstract H-1230b. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009). San Francisco, CA, September 12-15, 2009.
181. Wenner M. A cultured response to HIV. Nat Med 2009;15:594-597.